Oil Prices Edge Higher as U.S. Seizes Sanctioned Venezuelan Tanker 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Australia’s Labour Market Weakens as November Employment Drops Sharply 
U.S. Stock Futures Mixed as Tech and AI Stocks Face Pressure Ahead of CPI Data 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Asian Stocks Slip as Oracle Earnings Miss Sparks AI Profitability Concerns 
Nvidia Develops New Location-Verification Technology for AI Chips 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
China’s Small Bank Consolidation Struggles as Profits Fall and Risks Persist 
Asian Currencies Hold Steady as Indian Rupee Slides to Record Low on Fed Outlook 
Japanese beer and beverage maker Kirin is selling its China soft drinks joint venture to a Chinese investment fund, Plateau Consumer, for $994 million to enhance its pharmaceutical business.
The sale covers Kirin’s entire 40 percent stake in China Resources Kirin Beverages.
Established in 2011, China Resources Kirin Beverage had been expanding its business in China, making bottled water and bottled tea.
The move was part of its recent decision to review its investment portfolio, including foreign operations, under a management plan that runs through 2024. It comes shortly after Kirin decided to pull out of a joint venture brewery in Myanmar.
Kirin is focusing on certain areas, including pharmaceuticals and health science as well as food and beverages.
The Tokyo-based company has been streamlining its operations to focus on pharmaceutical projects like developing drugs for diseases that have no existing treatments and working on what it calls LC-Plasma to offer products that help maintain immune systems.
Kirin is among Japan’s top beer brands, and still has various global operations, including Four Roses Distillery in the U.S. and San Miguel Brewery in the Philippines.
.
